Research Synthesis: Alpha Ketoglutarate Akg

Abstract

This synthesis tests the thesis that evidence for Alpha-ketoglutarate is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Alpha-ketoglutarate (AKG), a central Krebs cycle intermediate and a cofactor for dioxygenases that regulate epigenetic marks, has drawn increasing attention as a potential modulator of aging, metabolic, and disease-related pathways.

This evidence synthesis was conducted using an AI-assisted structured review of 51 curated reference papers, applying transparent inclusion criteria and documenting the analytical audit trail for reproducibility.

The included literature spans preclinical, animal, and models, but is overwhelmingly preclinical or mechanistic in design, with only a single registered randomized controlled trial protocol identified (Sandalova 2023).

Translational relevance to humans remains uncertain.

The cross-study disagreement map reveals 476 non-orthogonal pairwise comparisons across outcome classes, with frequent null-versus-positive disagreements (severity 3–4) that preclude consensus on efficacy for any single human health endpoint.

Therefore, while preclinical mechanistic data on AKG's effects on oxidative stress, epigenetic regulation, and metabolic pathways are biologically plausible, the translational relevance to human health remains unestablished, and claims of clinical anti-aging or therapeutic benefit are not supported by the current evidence base.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-alpha_ketoglutarate_akg-v06-DAILY-2026-05-31T17-45-06Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-05-31.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• alpha-ketoglutarate AND aging AND human
• calcium alpha-ketoglutarate AND biological age
• AKG AND longevity AND trial
• alpha ketoglutarate AND epigenetic clock
• Ca-AKG AND safety AND human

Eligibility criteria

• Sources whose primary content addresses alpha ketoglutarate akg.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 184 records in the receipt-candidate union, 64 were classified as source candidates and 51 were admitted as traceable synthesis sources. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	184
Classified source candidates	64
No extractable claims	36
None-only claim binding	3
Partial/none-only claim binding	58
Partial-only candidates	15
Strict high-confidence sources	8
Admitted final sources	51

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Source verification in the public bundle is limited to reference-level metadata; reported statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, dosing and pharmacokinetics, immune, immune and inflammation, longevity, mortality and survival, safety and comorbidity, skeletal, fracture, and bone); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=30; claims=1738	null signal in 26/30 sources	24 indirect; 5 mechanistic; 1 review	limited corpus depth in this outcome class
Dosing and Pharmacokinetics	n=9; claims=314	null signal in 8/9 sources	8 indirect; 1 review	limited corpus depth in this outcome class
Cardiometabolic	n=3; claims=162	null signal in 3/3 sources	1 indirect; 2 mechanistic	limited corpus depth in this outcome class
Skeletal, Fracture, and Bone	n=3; claims=137	null signal in 2/3 sources	3 indirect	limited corpus depth in this outcome class
Safety and Comorbidity	n=2; claims=215	positive signal in 1/2 sources	2 mechanistic	limited corpus depth in this outcome class
Immune	n=1; claims=29	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Immune and Inflammation	n=1; claims=155	unclear signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating
Longevity	n=1; claims=2	null signal in 1/1 sources	1 mechanistic	single-source slice; hypothesis-generating
Mortality and Survival	n=1; claims=44	null signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

30 included sources were assigned to this outcome class. Directional coding: mixed=1, null=26, positive=1, unclear=2. Directness coding: indirect=24, mechanistic=5, review=1.

Dose / exposure Outcomes

9 included sources were assigned to this outcome class. Directional coding: null=8, unclear=1. Directness coding: indirect=8, review=1.

Cardiometabolic Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=1, mechanistic=2.

Skeletal Fracture Bone Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=2, unclear=1. Directness coding: indirect=3.

Safety Comorbidity Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=1, positive=1. Directness coding: mechanistic=2.

Immune Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Immune Inflammation Outcomes

1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: indirect=1.

Longevity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: mechanistic=1.

Mortality Survival Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by preclinical and mechanistic work, with the overwhelming majority of included studies conducted in cell lines (e.g., Greilberger 2023; Greilberger 2022), rodent models (e.g., An 2021; Takemura 2025; Huang 2025; Iniguez 2022; Iwaniak 2022; Qiu 2025), agricultural species such as pigs (Chen 2019; Sun 2025b; Sun 2025c; Tian 2023), carp (Wu 2021; Wu 2022), laying hens (Tomaszewska 2020; Tomaszewska 2021), and invertebrate or yeast organisms (Su 2019; Alpha-ketoglutarate 2018; Bayliak 2017; Burdyliuk 2017). No large-scale, long-duration randomized controlled trial assessing hard clinical endpoints — such as all-cause mortality, incident cardiovascular events, or cancer incidence — in human adults is represented. Consequently, the headline synthesis cannot draw conclusions about AKG's efficacy for the clinical endpoints most relevant to translational decision-making, and the apparent anti-aging signal described by Demidenko 2021 rests on retrospective DNA methylation data rather than prospective hard-outcome evidence.

Several outcome domains within this synthesis rest on findings from a single study, meaning that replication cannot be assessed within the corpus. For example, the cardiometabolic signal in diabetic mouse models comes solely from Takemura 2025 and Sun 2025, with no independent corroboration from human trials measuring glycemic endpoints such as HbA1c against the ADA 2024 target of 7%. Similarly, the longevity signal is supported only by Su 2019 in Drosophila and Alpha-ketoglutarate 2018, also in Drosophila, with no mammalian lifespan data in the corpus. Single-trial outcomes carry heightened risk of both type I error and idiosyncratic model effects, and the synthesis accordingly assigns low confidence to claims in these domains until corroborating evidence emerges.

Population external validity is severely constrained. The evidence consists of studies (Greilberger 2021; Greilberger 2021b; Greilberger 2022; Greilberger 2023; Dhat 2023) and agricultural-animal feeding trials that used doses — such as 10 g/kg AKG in piglet diets (Tian 2023), 1.0% AKG in laying-hen feed (Tomaszewska 2020), or 2% AKG in mouse drinking water (An 2021) — with no straightforward equivalence to human oral supplementation. No study enrolled older adults at risk of sarcopenia, where grip-strength cutoffs of 27 kg for men or 16 kg for women (Cruz-Jentoft 2019) might provide a relevant clinical frame. Diabetic populations are represented only by rodent STZ or high-fat-diet models (Takemura 2025; Dhat 2023; Qiu 2025), not by humans meeting the ADA 2024 HbA1c threshold of 7%. Ethnic diversity, sex-specific effects, and comorbidity burden in human cohorts are entirely unreported. The corpus therefore cannot inform AKG's safety or efficacy profile for the aging, frail, or chronically ill human populations most likely to seek supplementation.

Critical clinical endpoints were not measured in this corpus. The sole mortality-survival class entry (Huang 2025) reports flap survival in a murine skin-flap angiogenesis model, not human mortality. Additionally, the mechanism-to-clinic gap is substantial: most positive signals arise from mechanistic pathways — mTOR inhibition and AMPK activation in Drosophila (Su 2019), PI3K/Akt/HIF-1α-mediated angiogenesis (Huang 2025), NF-κB suppression (He 2017; Tian 2023b), and epigenetic histone demethylation (Sekita 2021; Hasegawa 2026) — yet no clinical trial in the corpus has tested whether these mechanistic effects translate to measurable patient-relevant benefit.

Conclusion

For alpha ketoglutarate akg, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence.

The strongest interpretation is that positive study-level signals are summarized in the safety and comorbidity and contextual adjacent evidence outcome classes, null signals in the contextual adjacent evidence, dosing and pharmacokinetics and cardiometabolic outcome classes, and negative signals in no dominant outcome class. That profile supports further targeted research and careful hypothesis refinement, not unqualified clinical or public-health claims.

Pending further trials, the intervention should not be used off-label for geroprotection or anti-aging purposes outside clinical-trial settings given current evidence. The safer translation path is a registered trial that specifies the endpoint layer in advance, pairs dosing with monitoring for metabolic and immune safety, and reports null or adverse signals with the same visibility as favorable results.

In animal/preclinical evidence, future work should prioritize studies that connect mechanistic studies (Qiu 2025, An 2021, Iwaniak 2022) to direct clinical outcomes represented by the retained evidence base. Until that bridge is stronger, alpha ketoglutarate akg remains a promising but bounded geroscience case whose most useful contribution is to define the next trial rather than to justify current clinical adoption.

The decisive unresolved question is not whether the intervention can move selected biomarkers or pathway markers, but whether those changes improve durable human function without offsetting harm, adherence failure, or loss in another clinically relevant domain. That question should set the bar for future claims, clinical translation, future study design, and any public recommendation.

What This Synthesis Adds

This synthesis maps 51 included sources on Alpha-ketoglutarate across 9 outcome classes and 476 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 51 curated reference papers, the evidence base for Alpha-ketoglutarate shows a context-dependent profile. Positive signals appear in: safety comorbidity, contextual other. Null findings dominate: contextual other, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Alpha-ketoglutarate anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

Additional corpus sources included animal/preclinical evidence; the strongest unresolved contrast is the disagreement between Dhat 2023 and Qiu 2025 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	null	direct clinical gap
cardiometabolic	0	3	null	direct clinical gap
immune	0	1	null	direct clinical gap
contextual adjacent evidence	0	30	mixed, null, positive, unclear	conflict-resolution gap
dosing and pharmacokinetics	0	9	null, unclear	direct clinical gap
safety and comorbidity	0	2	null, positive	direct clinical gap
skeletal, fracture, and bone	0	3	null, unclear	direct clinical gap
immune and inflammation	0	1	unclear	direct clinical gap
mortality and survival	0	1	null	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P2	cardiometabolic: direct clinical gap	0 direct and 3 indirect sources; direction profile: null
P3	immune: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P4	contextual adjacent evidence: conflict-resolution gap	0 direct and 30 indirect sources; direction profile: mixed, null, positive, unclear
P5	dosing and pharmacokinetics: direct clinical gap	0 direct and 9 indirect sources; direction profile: null, unclear

Next-Study Design Recommendation

The next high-yield study for Alpha-ketoglutarate should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

Additional corpus sources included animal/preclinical evidence; - Greilberger 2023; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.01.

• Greilberger 2022; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.01.
• Greilberger 2021; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.01.
• Wu 2022; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=immune inflammation; direction=unclear; representative statistic=P < 0.05.
• Tomaszewska 2020; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=skeletal fracture bone; direction=null.
• Wu 2021; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P < 0.05.
• Dhat 2023; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.0001.
• Tian 2023; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P < 0.05.
• Chen 2018; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=contextual other; direction=unclear; representative statistic=P = 0.027.
• Chen 2019; Observational; tier=B2; directness=indirect; N=—; population=adults; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P < 0.05.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 4 disagreement: Dhat 2023 vs Qiu 2025; Dhat 2023 (null) vs Qiu 2025 (mixed) on contextual other

• Severity 4 disagreement: Greilberger 2023 vs Qiu 2025; Greilberger 2023 (null) vs Qiu 2025 (mixed) on contextual other
• Severity 4 disagreement: Lamichhane 2023 vs Qiu 2025; Lamichhane 2023 (null) vs Qiu 2025 (mixed) on contextual other
• Severity 4 disagreement: Mohammadi 2025 vs Qiu 2025; Mohammadi 2025 (null) vs Qiu 2025 (mixed) on contextual other
• Severity 4 disagreement: Qiu 2025 vs Khamineh 2026; Qiu 2025 (mixed) vs Khamineh 2026 (null) on contextual other
• Severity 4 disagreement: Qiu 2025 vs Hasegawa 2026; Qiu 2025 (mixed) vs Hasegawa 2026 (null) on contextual other
• Severity 4 disagreement: Qiu 2025 vs Singh 2013; Qiu 2025 (mixed) vs Singh 2013 (null) on contextual other
• Severity 4 disagreement: Qiu 2025 vs Stuart 2014; Qiu 2025 (mixed) vs Stuart 2014 (null) on contextual other

Additional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Kaawaj 2020, Wang 2020, Showalter 2017, Liu 2022, Dilimulati 2026, Ruiz 2023, Cai 2016, Csaban 2021, Gai 2022, Mizerska-Kowalska 2022, Lin 2015, Wu 2016, Zhang 2020, Doroftei 2024, Fiehn 2016, Tinetti 1988.

References

• Greilberger 2023. Different RONS Generation in MTC-SK and NSCL Cells Lead to Varying Antitumoral Effects of Alpha-Ketoglutarate + 5-HMF. Current Issues in Molecular Biology, 2023. DOI: 10.3390/cimb45080410. PMID: 37623229.
• Greilberger 2022. Alpha-Ketoglutarate or 5-HMF: Single Compounds Effectively Eliminate Leukemia Cells via Caspase-3 Apoptosis and Antioxidative Pathways. International Journal of Molecular Sciences, 2022. DOI: 10.3390/ijms23169034. PMID: 36012295.
• Qiu 2025. Alpha-ketoglutarate rescues impaired endothelial progenitor cell-mediated angiogenesis in diabetic mice. Frontiers in Pharmacology, 2025. DOI: 10.3389/fphar.2025.1656473. PMID: 41181587.
• Greilberger 2021. Alpha-Ketoglutarate and 5-HMF: A Potential Anti-Tumoral Combination against Leukemia Cells. Antioxidants, 2021. DOI: 10.3390/antiox10111804. PMID: 34829675.
• Wu 2022. Low Protein Diets Supplemented With Alpha-Ketoglutarate Enhance the Growth Performance, Immune Response, and Intestinal Health in Common Carp ( Cyprinus carpio ). Frontiers in Immunology, 2022. DOI: 10.3389/fimmu.2022.915657. PMID: 35720284.
• An 2021. Alpha-ketoglutarate ameliorates pressure overload-induced chronic cardiac dysfunction in mice. Redox Biology, 2021. DOI: 10.1016/j.redox.2021.102088. PMID: 34364218.
• Tomaszewska 2020. Alpha-Ketoglutarate: An Effective Feed Supplement in Improving Bone Metabolism and Muscle Quality of Laying Hens: A Preliminary Study. Animals : an Open Access Journal from MDPI, 2020. DOI: 10.3390/ani10122420. PMID: 33348724.
• Wu 2021. Evaluation of Alpha-Ketoglutarate Supplementation on the Improvement of Intestinal Antioxidant Capacity and Immune Response in Songpu Mirror Carp ( Cyprinus carpio ) After Infection With Aeromonas hydrophila. Frontiers in Immunology, 2021. DOI: 10.3389/fimmu.2021.690234. PMID: 34220849.
• Iwaniak 2022. Dietary Alpha-Ketoglutarate Partially Abolishes Adverse Changes in the Small Intestine after Gastric Bypass Surgery in a Rat Model. Nutrients, 2022. DOI: 10.3390/nu14102062. PMID: 35631203.
• Takemura 2025. Alpha-ketoglutarate supplementation improves hyperglycemia and attenuates the decrease in GLUT4 and PGC-1α proteins in adipose tissue of streptozotocin-high-fat diet-induced diabetic mice. Journal of Nutritional Science, 2025. DOI: 10.1017/jns.2025.10059. PMID: 41496859.
• Sun 2025. Alpha-ketoglutarate mitigates insulin resistance and metabolic inflexibility in a mouse model of Ataxia-Telangiectasia. Nature Communications, 2025. DOI: 10.1038/s41467-025-64360-8. PMID: 41120320.
• Kaawaj 2020. Alpha Ketoglutarate Exerts In Vitro Anti-Osteosarcoma Effects through Inhibition of Cell Proliferation, Induction of Apoptosis via the JNK and Caspase 9-Dependent Mechanism, and Suppression of TGF-β and VEGF Production and Metastatic Potential of Cells. International Journal of Molecular Sciences, 2020. DOI: 10.3390/ijms21249406. PMID: 33321940.
• Dhat 2023. Epigenetic modifier alpha-ketoglutarate modulates aberrant gene body methylation and hydroxymethylation marks in diabetic heart. Epigenetics & Chromatin, 2023. DOI: 10.1186/s13072-023-00489-4. PMID: 37101286.
• Tian 2023. Dietary Alpha-Ketoglutarate Supplementation Improves Bone Growth, Phosphorus Digestion, and Growth Performance in Piglets. Animals : an Open Access Journal from MDPI, 2023. DOI: 10.3390/ani13040569. PMID: 36830356.
• Chen 2018. Alpha-Ketoglutarate in Low-Protein Diets for Growing Pigs: Effects on Cecal Microbial Communities and Parameters of Microbial Metabolism. Frontiers in Microbiology, 2018. DOI: 10.3389/fmicb.2018.01057. PMID: 29904374.
• Su 2019. Alpha-ketoglutarate extends Drosophila lifespan by inhibiting mTOR and activating AMPK. Aging (Albany NY), 2019. DOI: 10.18632/aging.102045. PMID: 31242135.
• Khamineh 2026. Effects of N-Acetylcysteine and Alpha-Ketoglutarate on OVCAR3 Ovarian Cancer Cells: Insights from Integrative Bioinformatics and Experimental Validation. Cells, 2026. DOI: 10.3390/cells15030281. PMID: 41677644.
• Chen 2019. Effects of Dietary Supplementation of Alpha-Ketoglutarate in a Low-Protein Diet on Fatty Acid Composition and Lipid Metabolism Related Gene Expression in Muscles of Growing Pigs. Animals : an Open Access Journal from MDPI, 2019. DOI: 10.3390/ani9100838. PMID: 31640132.
• Burdyliuk 2017. Effects of Long-Term Cultivation on Medium with Alpha-Ketoglutarate Supplementation on Metabolic Processes of Saccharomyces cerevisiae. Journal of Aging Research, 2017. DOI: 10.1155/2017/8754879. PMID: 29181198.
• Huang 2025. Alpha-ketoglutarate promotes random-pattern skin flap survival by enhancing angiogenesis via PI3K/Akt/HIF-1α signaling pathway. Cell Regeneration, 2025. DOI: 10.1186/s13619-025-00264-8. PMID: 41428315.
• Wang 2020. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nature Communications, 2020. DOI: 10.1038/s41467-020-19360-1. PMID: 33154378.
• Showalter 2017. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. eLife, 2017. DOI: 10.7554/eLife.26030. PMID: 28653623.
• Liu 2022. Alpha-ketoglutarate ameliorates abdominal aortic aneurysm via inhibiting PXDN/HOCL/ERK signaling pathways. Journal of Translational Medicine, 2022. DOI: 10.1186/s12967-022-03659-2. PMID: 36209172.
• Sandalova 2023. Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults (ABLE)—intervention study protocol. GeroScience, 2023. DOI: 10.1007/s11357-023-00813-6. PMID: 37217632.
• Tian 2023b. Elevation of Intracellular Alpha-Ketoglutarate Levels Inhibits Osteoclastogenesis by Suppressing the NF-κB Signaling Pathway in a PHD1-Dependent Manner. Nutrients, 2023. DOI: 10.3390/nu15030701. PMID: 36771407.
• Dilimulati 2026. Alpha-ketoglutarate enhances adipose-derived stem cells survival in wound healing by hypoxia-inducible factor 1-alpha-mediated redox homeostasis and glycogen-dependent bioenergetics. World Journal of Stem Cells, 2026. DOI: 10.4252/wjsc.v18.i2.113694. PMID: 41808885.
• He 2017. Alpha-ketoglutarate suppresses the NF-κB-mediated inflammatory pathway and enhances the PXR-regulated detoxification pathway. Oncotarget, 2017. DOI: 10.18632/oncotarget.16875. PMID: 29262538.
• Sun 2025b. Effects of Alpha-Ketoglutarate Supplementation on Growth Performance, Diarrhea Incidence, Plasma Amino Acid, and Nutrient Digestibility in Weaned Piglets. Animals : an Open Access Journal from MDPI, 2025. DOI: 10.3390/ani15121723. PMID: 40564275.
• Ruiz 2023. Alpha-Ketoglutarate Regulates Tnfrsf12a/Fn14 Expression via Histone Modification and Prevents Cancer-Induced Cachexia. Genes, 2023. DOI: 10.3390/genes14091818. PMID: 37761958.
• Bayliak 2017. Growth on Alpha-Ketoglutarate Increases Oxidative Stress Resistance in the Yeast Saccharomyces cerevisiae. International Journal of Microbiology, 2017. DOI: 10.1155/2017/5792192. PMID: 28154578.
• Tomaszewska 2021. Cholesterol Content, Fatty Acid Profile and Health Lipid Indices in the Egg Yolk of Eggs from Hens at the End of the Laying Cycle, Following Alpha-Ketoglutarate Supplementation. Foods, 2021. DOI: 10.3390/foods10030596. PMID: 33799887.
• Sun 2025c. Effects of Dietary Alpha-Ketoglutarate Supplementation on Diarrhea Incidence and Nutrient Digestibility in Weaned Piglets Fed Low-Protein Diets. Veterinary Sciences, 2025. DOI: 10.3390/vetsci12121163. PMID: 41472143.
• Iniguez 2022. Alpha-Ketoglutarate Promotes Goblet Cell Differentiation and Alters Urea Cycle Metabolites in DSS-Induced Colitis Mice. Nutrients, 2022. DOI: 10.3390/nu14061148. PMID: 35334805.
• Cai 2016. Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways. Scientific Reports, 2016. DOI: 10.1038/srep26802. PMID: 27225984.
• Demidenko 2021. Rejuvant®, a potential life-extending compound formulation with alpha-ketoglutarate and vitamins, conferred an average 8 year reduction in biological aging, after an average of 7 months of use, in the TruAge DNA methylation test. Aging (Albany NY), 2021. DOI: 10.18632/aging.203736. PMID: 34847066.
• Greilberger 2021b. Alpha-Ketoglutarate: A Potential Inner Mitochondrial and Cytosolic Protector against Peroxynitrite and Peroxynitrite-Induced Nitration?. Antioxidants, 2021. DOI: 10.3390/antiox10091501. PMID: 34573133.
• Lamichhane 2023. Lack of association of the alpha-ketoglutarate-dependent dioxygenase (FTO) gene polymorphisms with pulmonary tuberculosis risk: a systematic review and meta-analysis. Annals of Medicine and Surgery, 2023. DOI: 10.1097/MS9.0000000000001188. PMID: 37811091.
• Sekita 2021. AKT signaling is associated with epigenetic reprogramming via the upregulation of TET and its cofactor, alpha-ketoglutarate during iPSC generation. Stem Cell Research & Therapy, 2021. DOI: 10.1186/s13287-021-02578-1. PMID: 34563253.
• Csaban 2021. The Role of the Rare Variants in the Genes Encoding the Alpha-Ketoglutarate Dehydrogenase in Alzheimer’s Disease. Life, 2021. DOI: 10.3390/life11040321. PMID: 33917565.
• Gai 2022. Foliar application of alpha-ketoglutarate plus nitrogen improves drought resistance in soybean ( Glycine max L. Merr. ). Scientific Reports, 2022. DOI: 10.1038/s41598-022-18660-4. PMID: 36002532.
• Mohammadi 2025. Repurposing FDA-approved drugs to find a novel inhibitor of alpha-ketoglutarate-dependent dioxygenase FTO to treat esophageal cancer. Research in Pharmaceutical Sciences, 2025. DOI: 10.4103/RPS.RPS_9_25. PMID: 40687281.
• Stuart 2014. A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer & Metabolism, 2014. DOI: 10.1186/2049-3002-2-4. PMID: 24612826.
• Mizerska-Kowalska 2022. Alpha Ketoglutarate Downregulates the Neutral Endopeptidase and Enhances the Growth Inhibitory Activity of Thiorphan in Highly Aggressive Osteosarcoma Cells. Molecules, 2022. DOI: 10.3390/molecules28010097. PMID: 36615293.
• Singh 2013. Effect of Alpha-Ketoglutarate on Growth and Metabolism of Cells Cultured on Three-Dimensional Cryogel Matrix. International Journal of Biological Sciences, 2013. DOI: 10.7150/ijbs.4962. PMID: 23781146.
• Lin 2015. D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2. Nature Communications, 2015. DOI: 10.1038/ncomms8768. PMID: 26178471.
• Alpha-ketoglutarate 2018. Effects of alpha-ketoglutarate on lifespan and functional aging of Drosophila melanogaster flies. The Ukrainian Biochemical Journal, 2018. DOI: 10.15407/ubj90.06.049.
• Hasegawa 2026. Alpha-Ketoglutarate Drives an Osteogenic and Extracellular Matrix Gene Program in Periodontal Ligament Fibroblasts via Selective Reduction of H3K27me3. Biology, 2026. DOI: 10.3390/biology15050372. PMID: 41823800.
• Wu 2016. Alpha-Ketoglutarate: Physiological Functions and Applications. Biomolecules & Therapeutics, 2016. DOI: 10.4062/biomolther.2015.078. PMID: 26759695.
• Zhang 2020. Alpha-ketoglutarate utilization in Saccharomyces cerevisiae : transport, compartmentation and catabolism. Scientific Reports, 2020. DOI: 10.1038/s41598-020-69178-6. PMID: 32733060.
• Doroftei 2024. A scoping review regarding reproductive capacity modulation based on alpha-ketoglutarate supplementation. Reproduction (Cambridge, England), 2024. DOI: 10.1530/REP-24-0137. PMID: 39189990.
• Fiehn 2016. Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. eLife, 2016. DOI: 10.7554/eLife.12626. PMID: 26943899.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• ADA 2024. American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1). DOI: 10.2337/dc24-S006.
• Cruz-Jentoft 2019. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16-31. DOI: 10.1093/ageing/afy169. PMID: 30312372.
• Tinetti 1988. Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707. DOI: 10.1056/NEJM198812293192604. PMID: 3205267.